Regeneron Pharmaceuticals and Tessera Therapeutics Team Up
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has entered into an exciting global collaboration with Tessera Therapeutics, Inc. The aim of this partnership is to develop and commercialize their leading investigational program, TSRA-196. This initiative is set to make significant strides in addressing a rare genetic disorder.
Understanding Alpha-1 Antitrypsin Deficiency (AATD)
Alpha-1 antitrypsin deficiency (AATD) is an inherited condition that affects the production of a protein crucial for protecting the lungs and liver. When the body does not produce enough alpha-1 antitrypsin (AAT), it can lead to severe health complications. This genetic disorder currently affects around 200,000 individuals across regions.
Benefits of TSRA-196
The TSRA-196 program is designed to precisely rectify the genetic mutation responsible for AATD. By using a one-time gene therapy approach, it offers a durable treatment solution, potentially restoring the production of functional AAT protein for patients. The results from this program could significantly improve the quality of life for those afflicted by this condition.
Collaboration and Financial Commitment
As part of the collaboration agreement, Regeneron will contribute $150 million, which includes both a cash upfront payment and equity investment in Tessera. Furthermore, Tessera stands to gain additional milestone payments totaling $125 million based on near and mid-term development progress. This financial backing underscores the commitment both companies have towards the success of TSRA-196.
Future Steps in the Development Process
Looking ahead, Tessera plans to file an Investigational New Drug application along with multiple Clinical Trial Applications for TSRA-196 with the U.S. Food and Drug Administration (FDA) by the end of the current year. Tessera is set to lead the first-in-human trial, while Regeneron will take the lead in global development and commercialization.
Progress in Preclinical Trials
This collaboration builds on Tessera's recent advancements in the TSRA-196 program, including promising preclinical data showcased at a prestigious annual meeting. These findings revealed robust genome editing capabilities, specifically targeting the SERPINA1 locus, which is critical for AAT production.
Safety and Tolerability
The preclinical results highlighted the high specificity of liver editing, showing no off-target effects or germline alterations, which adds to the safety profile of TSRA-196. The proprietary lipid nanoparticle delivery system utilized during these studies has shown favorable safety and tolerability metrics.
Market Reception and Share Performance
As of now, Regeneron stock has experienced a minor downturn, with prices reported at $756.40, reflecting a 3.02% drop. This fluctuation is not uncommon as the market reacts to new developments and collaborations. Investors and stakeholders are optimistic about the potential success of TSRA-196.
Frequently Asked Questions
What is TSRA-196?
TSRA-196 is an investigational one-time gene therapy developed to treat alpha-1 antitrypsin deficiency (AATD) by correcting genetic mutations.
How does alpha-1 antitrypsin deficiency affect health?
AATD leads to insufficient AAT protein production, which can harm the lungs and liver, resulting in various health complications.
What are the financial implications of the Regeneron and Tessera partnership?
Regeneron will invest $150 million upfront and provide additional milestone payments of $125 million based on development achievements for TSRA-196.
When can we expect clinical trials for TSRA-196?
Tessera aims to file applications for TSRA-196 with the FDA by the end of this year to begin initial human trials.
What recent findings support the efficacy of TSRA-196?
Recent preclinical data demonstrated effective genome editing and safety, indicating potential for successful treatment outcomes in humans.
